Navigation Links
Abbott Receives CE Mark for Smaller-Size XIENCE(TM) V Drug Eluting Stent
Date:3/10/2008

New 2.25 mm Diameter Stent Now Available in Europe, Asia and Latin America

ABBOTT PARK, Ill., March 11 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) announced today that it has received CE Mark (Conformite Europeene) approval for a 2.25 mm version of its XIENCE(TM) V Everolimus Eluting Coronary Stent System, offering physicians a smaller stent based upon the proven efficacy, positive safety results and excellent deliverability of XIENCE V. The addition of the 2.25 mm stent to the XIENCE V portfolio gives physicians access to a wider range of stent sizes for treating a variety of patient types.

"Lesions in small vessels tend to be more complex and challenging to treat, so it's important to have a drug eluting stent with proven clinical benefits that can be easily delivered to the diseased area of the vessel," said Charles Simonton, M.D., FACC, FSCAI, divisional vice president, Medical Affairs and chief medical officer, Abbott Vascular. "With XIENCE V 2.25 mm, physicians now have access to a smaller stent that combines these critical attributes with the positive safety outcomes we have seen with XIENCE V. These outcomes include low rates of reintervention in the diseased vessel, low rates of heart attack and death, and low rates of vessel renarrowing following treatment."

The 2.25 mm version of the XIENCE V stent will be launched immediately in the majority of European markets and select countries in Asia and Latin America. In addition to the 2.25 mm stent, XIENCE V is available in stent diameters of 2.5 mm, 2.75 mm, 3.0 mm, 3.5 mm and 4.0 mm for lesions 28 mm or shorter.

Coronary artery disease (CAD) occurs when arteries become narrow due to plaque buildup, restricting blood flow to the heart. Approximately 30 to 40 percent of CAD lesions occur in vessels equal to or less than 2.5 mm in diameter.

XIENCE V is the only drug eluting stent to demonstrate superiority over another drug eluting stent in a randomized clinical trial. In t
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Abbott, Genentech and WEHI Collaborate to Research and Develop New Anti-Cancer Drugs
2. Abbott Receives FDA Approval for HUMIRA(R) (Adalimumab) for Polyarticular Juvenile Idiopathic Arthritis
3. Abbott Announces 10.8 Percent Increase in Quarterly Dividend
4. On Valentines Day, Abbott Urges Women to Take Heart With Launch of Faces of Heart Disease Exhibit to Raise Heart Health Awareness
5. Abbott Goes Red to Educate Bay Area Women About Heart Disease
6. Abbott to Present at Merrill Lynch Healthcare Conference
7. Abbotts Kaletra(R) and Aluvia(R) (lopinavir/ritonavir) New Lower-Strength Tablet for Pediatric Use Receives Positive Opinion from EMEA
8. Abbott Hosts Conference Call for Fourth-Quarter and Full-Year 2007 Earnings
9. Cookie Johnson and Abbott Bring I Stand With Magic: Campaign to End Black AIDS to Los Angeles to Educate African-American Women on HIV/AIDS
10. Ugandan Children Are Among the First to Receive Abbotts Lower-Strength Aluvia (lopinavir/ritonavir) Tablet
11. The Magic Johnson Foundation and Abbott Expand Focus of Campaign to End Black AIDS to African-American Women in 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Pregnant women who live in leafy, green neighborhoods are less ... new study suggests. Researchers analyzed data from more than ... who lived in a neighborhood with plenty of trees, grass ... very preterm birth (before 30 weeks) and a 13 percent ... Babies born to mothers who lived in greener neighborhoods ...
(Date:9/19/2014)... Alan Mozes HealthDay Reporter ... patients burdened by stress and family conflicts before surgery ... operation, a new study suggests. Investigators found that ... a nearly three times greater risk for complications compared ... life. "We,ve long known that patient quality of ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 MetroMD, a leading ... the “God Particle” of human health. This therapy has grown ... making the therapy more effective, safe and dependable. It has ... them an opportunity to live a very healthy and active ... concept of HGH therapy, a senior therapist at MetroMD said, ...
(Date:9/19/2014)... In partnership with Raw Beauty NYC, ... of the project’s social media efforts. StudioPMG is honored to ... the perception of beauty as it applies to disabled women. ... by Shelly Baer and Vanessa Silberman, who wanted to create ... beautiful. Ginny Dixon, Wendy Crawford, Susan Solman and Sabrina Cohen ...
(Date:9/19/2014)... to reducing poverty that help children and their ... and foundations. By combining education and training for ... that offer a path out of poverty with ... programs aim to improve the life opportunities of ... from the National Center for Children in Poverty ...
Breaking Medicine News(10 mins):Health News:Do Greener Neighborhoods Produce Healthier Babies? 2Health News:Family Squabbles Can Derail Recovery From Cancer Surgery 2Health News:Family Squabbles Can Derail Recovery From Cancer Surgery 3Health News:MetroMD Announces Better HGH Therapy - the ‘God Particle’ of Human Health 2Health News:OC Healthcare Agency StudioPMG Partners with The Raw Beauty Project ™ NYC 2014 2Health News:A two generation lens: Current state policies fail to support families with young children 2
... Jan. 31 (HealthDay News) -- Super Bowl fans, beware: ... and the Green Bay Packers could be a killer, ... withstand the emotional stress that comes with watching the ... risk appears real, a Los Angeles-based study team cautions, ...
... bacteria to build an extra natural layer of nanoparticle-like armour ... a startlingly simple way to give drug bearing polymer vesicles ... The Warwick researchers have been able to decorate ... new strategy in the design of vehicles for drug release, ...
... is a pathological syndrome that is usually classified into ... the Milwaukee criteria. However, this classification has some drawbacks ... classification and failure to properly guide diagnosis and treatment. ... in the World Journal of Gastroenterology addresses ...
... Oncology (ISCO) will collaborate to publish Cellular Oncology ... the official journal of ISCO and publishes original papers ... It was previously published by IOS Press. ... clinical disciplines involved in basic and translational cancer research ...
... , SATURDAY, Jan. 29 (HealthDay News) -- An ... decided on Friday that electroconvulsive (also known as "electroshock") ... as other medical devices entering the market. ... decades-old controversy surrounding the psychiatric treatment, which some patients ...
... Jan. 30 (HealthDay News) -- It may not be news to those ... reports that if you,re aboard a ship, looking at the horizon can ... investigators compared a group of crew members as they stood on land ... front of them and then a far-off object -- a distant mountain ...
Cached Medicine News:Health News:Super Bowl Loss Really a Heart Stopper for Some Fans 2Health News:Super Bowl Loss Really a Heart Stopper for Some Fans 3Health News:Plankton inspires creation of stealth armor for slow-release microscopic drug vehicles 2Health News:Springer to publish Cellular Oncology 2Health News:FDA Panel Recommends Testing of Electroshock Devices 2Health News:FDA Panel Recommends Testing of Electroshock Devices 3Health News:FDA Panel Recommends Testing of Electroshock Devices 4
(Date:9/19/2014)... The Parenteral Drug Association (PDA) is moving ... protocols. The new initiative stems from ... industry participants and regulatory authority representatives at the PDA ... Washington, DC . Representatives of both the ... workshop. Attendees indicated openness to engaging regulators and industry ...
(Date:9/19/2014)... Calif. , Sept. 19, 2014 Today, iHealth ... capital from Xiaomi Ventures, Ltd. for its first institutional ... to continue expanding iHealth,s global reach, accelerate growth and ...  As part of the investment, Xiaomi Ventures will join ... areas of cloud infrastructure and ecommerce. "We ...
(Date:9/19/2014)... DUBLIN , September 19, 2014 /PRNewswire/ ... http://www.researchandmarkets.com/research/s6g5wm/global ) has announced the addition of ... report to their offering. ... devices have been broadly classified into wide ... are used for the treatment of different ...
Breaking Medicine Technology:PDA Launches Effort to Harmonize Global Post-Approval Changes Protocols 2iHealth Raises $25 Million to Fuel Growth and Global Market Share 2Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 2Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 3
BD Vacutainer® Heparin Tubes are spray-coated with either lithium heparin or sodium heparin and are used for plasma determinations in chemistry....
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
... Coagulation tubes contain a buffered ... available with a citrate concentration ... 0.129 mol/l (3.8%). The mixing ... solution to 9 parts blood. ...
... are available in two versions. ... a clotting activator and is ... serum is required for testing ... is suitable where the testing ...
Medicine Products: